Point of Care Test for Vaginal Infections

(PAT Trial)

IM
JH
Overseen ByJamie Haggerty
Age: Any Age
Sex: Female
Trial Phase: Academic
Sponsor: Sharon L Hillier
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a quick, in-office test can diagnose and treat vaginal infections more effectively than usual methods. Participants will receive either a typical evaluation or a point-of-care test, the Xpert® Xpress MVP test, which provides results in about an hour. Researchers seek to discover which approach leads to better diagnosis, treatment, and patient satisfaction. Individuals experiencing symptoms like unusual discharge, odor, or itching for less than two months and seeking care may be suitable for this study. As an unphased study, this trial offers an opportunity to contribute to innovative research that could enhance diagnostic methods for vaginal infections.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your healthcare provider.

What prior data suggests that this point of care test is safe for diagnosing vaginal infections?

Research has shown that the Xpert® Xpress MVP test is safe for diagnosing vaginal infections. The FDA has approved this test, confirming its safety and effectiveness. As a point-of-care test, it can quickly provide results during a doctor's visit by detecting DNA from bacteria and fungi that commonly cause vaginal infections.

Since the test is FDA-cleared and widely used in medical settings, no major safety issues have been reported. It does not involve medication or invasive methods, reducing the risk of side effects. Participants in studies have not reported any harmful effects from the test itself.

In summary, past research and current use indicate that the Xpert® Xpress MVP test is well-tolerated and considered safe.12345

Why are researchers excited about this trial?

Researchers are excited about the Xpert® Xpress MVP test because it offers a rapid, on-the-spot diagnosis for vaginal infections, delivering results in about an hour. Unlike standard methods, which rely on traditional lab cultures or clinician evaluations that can take days, this test provides immediate data that can guide treatment decisions during the same office visit. This immediacy not only enhances patient care by enabling quicker, more accurate treatment but also reduces the anxiety and inconvenience of waiting for lab results.

What evidence suggests that the Xpert® Xpress MVP test is effective for diagnosing vaginal infections?

Research shows that the Xpert Xpress MVP test excels at diagnosing vaginal infections. Studies have found it to be both highly sensitive and specific, accurately detecting infections such as bacterial vaginosis, yeast infections, and trichomoniasis. In this trial, participants in the "Same Day Results" arm will have the Xpert Xpress MVP test conducted in real time during their office visit, providing results in about an hour. This rapid option enables providers to use the test results for immediate diagnosis and treatment. The FDA has approved the test, which can be used in clinics with minimal handling, quickly assisting doctors in selecting the best treatment for these common infections.15678

Who Is on the Research Team?

SL

Sharon L Hillier, PhD

Principal Investigator

University of Pittsburgh

Are You a Good Fit for This Trial?

This trial is for individuals experiencing symptoms of vaginal infections such as Bacterial Vaginosis, Trichomoniasis, Yeast infection, or Vaginitis. Participants will be assessed using either usual care methods or a new point-of-care test to diagnose and treat their condition.

Inclusion Criteria

Seeking care at one of the participating offices
Able and willing to provide informed consent
Willing to undergo all study-related assessments and procedures, including self-collection of vaginal swabs, answering questions/surveys, agreeing to the review and collection of information from their medical record from the office (enrollment/index) visit and up to 4 weeks after the office visit
See 3 more

Exclusion Criteria

Previous participation in this study
Any condition, that in the opinion of the investigator, would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1 day
1 visit (in-person)

Treatment

Participants receive diagnosis and treatment based on either usual care or point-of-care test results during the office visit

1 day
1 visit (in-person)

Follow-up

Participants are contacted to assess symptom resolution and satisfaction with their visit

2 weeks
1 contact (telephone)

Medical Record Review

Review of medical records related to vaginal complaints up to 30 days from enrollment

30 days

What Are the Treatments Tested in This Trial?

Interventions

  • Xpert® Xpress MVP test
Trial Overview The study compares the effectiveness of standard diagnostic practices (usual care) with a new FDA-approved point-of-care test called Xpert® Xpress MVP in diagnosing and treating vaginal infections. Patients are randomly assigned to one of these two approaches.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Usual CareExperimental Treatment1 Intervention
Group II: Same Day ResultsExperimental Treatment1 Intervention

Xpert® Xpress MVP test is already approved in United States for the following indications:

🇺🇸
Approved in United States as Xpert Xpress MVP for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sharon L Hillier

Lead Sponsor

Trials
1
Recruited
350+

Cepheid

Industry Sponsor

Trials
24
Recruited
10,500+

Published Research Related to This Trial

The GeneXpert point-of-care test for chlamydia and gonorrhoea was found to be highly acceptable among primary care staff in remote Australia, improving the management of STIs by enabling timely and targeted treatment.
Staff reported increased confidence in test results and greater job satisfaction, although some challenges with manual documentation and managing positive results were noted, suggesting a need for better electronic systems to enhance efficiency.
"I Do Feel Like a Scientist at Times": A Qualitative Study of the Acceptability of Molecular Point-Of-Care Testing for Chlamydia and Gonorrhoea to Primary Care Professionals in a Remote High STI Burden Setting.Natoli, L., Guy, RJ., Shephard, M., et al.[2019]
Self-testing for bacterial vaginosis (BV) by young women showed good agreement with clinician-performed tests, with the self-pH test demonstrating 73% sensitivity and 67% specificity compared to clinical diagnosis.
Trust in self-testing increased after participants performed the tests and discussed the results, although initial trust was lower than for clinician-performed tests, indicating potential for self-testing to enhance access to BV diagnosis.
Accuracy and trust of self-testing for bacterial vaginosis.Huppert, JS., Hesse, EA., Bernard, MC., et al.[2021]
The Xpert Xpress MVP test showed high accuracy in diagnosing vaginitis/vaginosis, with positive agreement rates between 93.6% and 99.0% and negative agreement rates between 92.1% and 99.8% for both clinician-collected and self-collected samples.
Conducted across 12 diverse clinical sites in the U.S., this study suggests that the MVP test could be a reliable diagnostic tool in both laboratory and point-of-care settings for patients with symptoms of vaginitis/vaginosis.
Clinical Evaluation of a New Molecular Test for the Detection of Organisms Causing Vaginitis and Vaginosis.Lillis, RA., Parker, RL., Ackerman, R., et al.[2023]

Citations

Clinical Evaluation of a New Molecular Test for the ...The Xpert Xpress MVP test was both highly sensitive and specific for the diagnosis of the most common causes of vaginitis/vaginosis, all from the same vaginal ...
Xpert® Xpress MVPMultiplex vaginal panel that enables results within 60 minutes from a single specimen for Bacterial Vaginosis, Vulvovaginal Candidiasis & Trichomoniasis.
A 510(k) Number K231381 B Applicant CephThe Xpert Xpress MVP test is intended to aid in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, ...
Evaluation of the user experience for a point of care molecular ...The Xpert Xpress MVP test is the first CLIA-waived, FDA-cleared POC NAAT for diagnosing vaginal infections within an hour with minimal hands-on ...
NCT06438575 | Point of Care Diagnosis of Vaginal InfectionsA positive result from both the Xpert® Xpress MVP and the BD MAX™ Vaginal Panel will be considered the gold standard for diagnosis of vaginitis/vaginosis.
K21 - accessdata.fda.govThe Xpert Xpress MVP test includes reagents for the detection of DNA from BV organisms,. Candida species, and Trichomonas vaginalis from vaginal ...
Xpert Xpress MVPThe Xpert Xpress MVP test is intended to aid in the diagnosis of vaginal infections ... Safety Data Sheets (SDS) are available at www.cepheid.com or www ...
K231381 Trade/Device Name - accessdata.fda.govThe analytical reactivity of the Xpert Xpress MVP test was determined with 5 strains of Candida albicans, 5 strains of Candida dubliniensis, 5 ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security